Kura Oncology (NASDAQ:KURA) Share Price Up 3.9%

Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report ) traded up 3.9% on Wednesday. The stock traded as high as $20.95 and last traded at $20.95. 64,472 shares were traded mid-day, down 93% from the session’s average volume of 950,172 shares. Shares previously closed at $20.16.

Analysts on Wall Street are forecasting an increase

Several equities research analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Monday, September 9th. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Friday, August 9th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Finally, Stifel Nicolaus cut their price target on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Kura Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $30.60, based on data from MarketBeat.com.

Get the latest research report on KURA

Kura Oncology trading up 1.0%

The stock’s fifty-day simple moving average is $20.30, and its 200-day simple moving average is $20.63. The firm has a market cap of $1.55 billion, a PE ratio of -9.29 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94, and a quick ratio of 14.94.

Kura Oncology (NASDAQ:KURA – Get Your Free Report ) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. In the same quarter last year, the firm posted earnings per share of ($0.53). Kura Oncology’s revenue for the quarter was up 0.0% on a year-over-year basis. On average, sell-side analysts estimate that Kura Oncology, Inc. will post -2.45 earnings per share for the current year.

Institutional inputs and outputs

Several institutional investors have recently made changes to their positions in KURA. Charles Schwab Investment Management Inc. raised its holdings in shares of Kura Oncology by 2.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 579,987 shares of the company’s stock worth $8,340,000 after buying an additional 16,566 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Kura Oncology by 69.2% in the fourth quarter. BNP Paribas Financial Markets now owns 91,801 shares of the company’s stock worth $1,320,000 after buying an additional 37,550 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Kura Oncology by 10.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock worth $28,785,000 after buying an additional 197,530 shares in the last quarter. Trexquant Investment LP boosted its holdings in shares of Kura Oncology by 74.4% in the fourth quarter. Trexquant Investment LP now owns 64,027 shares of the company’s stock worth $921,000 after buying an additional 27,312 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Kura Oncology by 10.7% during the fourth quarter. Franklin Resources Inc. now owns 1,353,665 shares of the company’s stock worth $19,466,000 after buying an additional 130,710 shares during the last quarter.

Kura Oncology Company Profile

(Get a free report)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer. The company’s pipeline consists of small molecule product candidates targeting cancer. The lead product candidate is ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subgroups of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Read more

Get news and reviews for Kura Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kura Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.